Adaptimmune Therapeutics PLC - SPONDS ADR (ADAP)

Historical Portfolio Holders from Q2 2015 to Q3 2024

All holders as of September 30, 2024
Q3 2024
Type / Class
Equity / SPONDS ADR
Shares, excl. options Q3 2024
152M
Holdings value Q3 2024
$144M
Value change Q3 2024
-$2.35M
Grand Portfolio weight change Q3 2024
0%
Number of holders
77
Number of buys Q3 2024
35
Number of sells Q3 2024
-26
Average buys Q3 2024 %
+0%
Average sells Q3 2024 %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Period Shares, Excl. Options Value, Excl. Options Change Price Investors
2024 Q3 152M $144M -$2.35M $0.95 78
2024 Q2 154M $150M -$8.88M $0.97 75
2024 Q1 162M $256M +$30.6M $1.58 77
2023 Q4 144M $114M -$3.75M $0.79 75
2023 Q3 148M $116M +$2.66M $0.78 76
2023 Q2 145M $134M +$26.6M $0.93 84
2023 Q1 116M $126M +$2.11M $1.09 62
2022 Q4 114M $166M +$521K $1.46 63
2022 Q3 114M $122M -$1.59M $1.08 60
2022 Q2 115M $195M +$7.48M $1.70 70
2022 Q1 109M $224M -$22.1M $2.06 73
2021 Q4 113M $426M -$9.03M $3.75 80
2021 Q3 112M $577M +$3.04M $5.17 90
2021 Q2 112M $476M -$26.2M $4.26 80
2021 Q1 117M $624M -$3.87M $5.31 80
2020 Q4 118M $637M -$92.1M $5.39 86
2020 Q3 130M $1.04B +$4.54M $7.98 76
2020 Q2 128M $1.28B +$369M $10.01 77
2020 Q1 93.8M $255M +$79.5M $2.72 45
2019 Q4 64.9M $77.9M -$4.19M $1.20 36
2019 Q3 68.1M $103M -$1.4M $1.51 41
2019 Q2 68.2M $274M -$5.12M $4.02 54
2019 Q1 69.4M $298M -$2.01M $4.30 62
2018 Q4 69.1M $397M -$4.29M $5.75 74
2018 Q3 65.5M $888M +$132M $13.56 89
2018 Q2 55.9M $663M -$2.4M $11.87 87
2018 Q1 56.2M $631M +$52.1M $11.23 75
2017 Q4 52.1M $348M +$7.24M $6.68 69
2017 Q3 50.8M $416M +$29.1M $8.19 66
2017 Q2 48.1M $216M +$37.7M $4.49 53
2017 Q1 39.8M $218M +$54.9M $5.51 48
2016 Q4 29.8M $121M -$7.12M $4.05 39
2016 Q3 30.9M $218M -$7.77M $7.05 46
2016 Q2 31.9M $260M -$1.11M $8.15 46
2016 Q1 32M $260M +$87.4M $8.13 48
2015 Q4 20.6M $249M +$66M $12.06 47
2015 Q3 15.2M $181M -$67.5M $11.97 41
2015 Q2 21M $384M +$375M $18.33 45